G207

Phase 2Biologic

MM.D. Anderson Cancer Center

G207 is one of 2 biologic programs targeting High Grade Gliomas. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

High Grade GliomasNot yet recruiting

Neoplasms, BrainRecruiting

High Grade GliomasPhase 2

Not yet recruiting

Neoplasms, BrainPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in High Grade Gliomas

#DrugCompanyPhaseTrials

Azeliragon

CCantex Pharmaceuticals

Phase 2

1 2

G207

MM.D. Anderson Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Neoplasms, Brain

NCT03911388

Q4 2032

Phase 2Not yet recruiting

High Grade Gliomas

NCT07649070

Clinical

Trials by Indication[1]

Supratentorial Brain Tumor1 trial

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

Completed·—·Phase 1·NCT02457845·13 enrolled

Malignant Glioma1 trial

G207 Followed by Radiation Therapy in Malignant Glioma

Completed·MMediGene·Phase 1·NCT00157703·9 enrolled

Neoplasms, Brain1 trial

Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03911388·24 enrolled

High Grade Gliomas1 trial

Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07649070·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for G207. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — G207 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for G207. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

G207

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2032

Trials by Indication[1]

Supratentorial Brain Tumor1 trial

Malignant Glioma1 trial

Neoplasms, Brain1 trial

High Grade Gliomas1 trial

References

Drug Info

Quick Facts

Related News